Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting

Schedule of reportable operating segment information

	CareVention HealthCare		Shared Services and Other		Consolidated
Revenue:
Three Months Ended September 30, 2022
Product revenue	$	59,780	$	—	$	59,780
Service revenue
PACE solutions		16,416		—		16,416
Medication safety services		—		843		843
Software subscription and services		—		62		62
Total service revenue		16,416		905		17,321
Total revenue	$	76,196	$	905	$	77,101
Three Months Ended September 30, 2021
Product revenue	$	50,321	$	—	$	50,321
Service revenue
PACE solutions		14,707		—		14,707
Medication safety services		—		2,820		2,820
Software subscription and services		—		62		62
Total service revenue		14,707		2,882		17,589
Total revenue	$	65,028	$	2,882	$	67,910
Nine Months Ended September 30, 2022
Product revenue	$	166,645	$	—	$	166,645
Service revenue
PACE solutions		47,604		—		47,604
Medication safety services		—		2,336		2,336
Software subscription and services		—		223		223
Total service revenue		47,604		2,559		50,163
Total revenue	$	214,249	$	2,559	$	216,808
Nine Months Ended September 30, 2021
Product revenue	$	139,021	$	—	$	139,021
Service revenue
PACE solutions		42,973		—		42,973
Medication safety services		—		8,817		8,817
Software subscription and services		—		174		174
Total service revenue		42,973		8,991		51,964
Total revenue	$	181,994	$	8,991	$	190,985

	CareVention HealthCare		Shared Services and Other		Consolidated
Adjusted EBITDA (loss) from Continuing Operations:
Three Months Ended September 30, 2022
Adjusted EBITDA (loss)	$	14,051	$	(11,998)	$	2,053
Three Months Ended September 30, 2021
Adjusted EBITDA (loss)	$	14,014	$	(10,875)	$	3,139
Nine Months Ended September 30, 2022
Adjusted EBITDA (loss)	$	39,531	$	(34,339)	$	5,192
Nine Months Ended September 30, 2021
Adjusted EBITDA (loss)	$	40,983	$	(32,998)	$	7,985

Schedules of reconciliation of net loss to Adjusted EBITDA

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations
Net loss	$	(40,065)	$	(17,111)	$	(117,868)	$	(57,684)
Add:
Interest expense, net		2,717		2,230		7,430		6,959
Income tax (benefit) expense		(7)		82		368		284
Depreciation and amortization		5,723		5,328		16,954		15,109
Impairment charges		—		—		4,062		—
Business optimization expenses		—		—		787		—
Severance costs		122		354		697		516
Executive transition		1,821		—		1,971		—
Cooperation agreement costs		1,122		—		1,122		—
Divestiture-related expense		1,057		—		2,591		—
Acquisition-related expense		—		—		—		217
Stock-based compensation expense		15,378		6,901		28,173		24,100
Loss from discontinued operations		14,185		5,355		58,905		18,484
Adjusted EBITDA from continuing operations	$	2,053	$	3,139	$	5,192	$	7,985
Adjusted EBITDA (loss) from discontinued operations		(3,593)		2,578		(1,036)		7,294
Total Adjusted EBITDA (loss)	$	(1,540)	$	5,717	$	4,156	$	15,279

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA (Loss) from Discontinued Operations
Net loss from discontinued operations, net of tax	$	(14,185)	$	(5,355)	$	(58,905)	$	(18,484)
Add:
Income tax (benefit) expense		(94)		52		(662)		182
Depreciation and amortization		—		6,771		7,331		20,234
Impairment charges		5,845		—		42,293		—
Loss on disposal of business		2,879		—		2,879		—
Settlement		—		—		1,448		500
Divestiture-related expense		104		—		216		—
Stock-based compensation expense		1,858		1,110		4,364		4,862
Adjusted EBITDA (loss) from discontinued operations	$	(3,593)	$	2,578	$	(1,036)	$	7,294